Skip to main content

National rules are needed about restriction of NHS prescriptions for drugs available over the counter

A recent news article in the BMJ reported that many clinical commissioning groups (CCGs) in England are trying to restrict NHS prescriptions for drugs that are also available over the counter (OTC). This would include, for example, drugs such as antihistamines. This raises a number of issues. Firstly, CCGs have no legal power to limit the prescribing of drugs by GPs (although many CCGs and GPs don’t seem to know this). The only drugs that GPs are not allowed to prescribe are those listed in Part XVIIIA of the NHS Drug Tariff (sometimes referred to as the ‘blacklist’). 

Secondly, rather than going through a formal process and asking the Department of Health to place additional drugs on the ‘blacklist’, CCGs seem content to let doctors decide who should have these drugs on NHS prescription and who should not. This will inevitably lead to considerable variation between GPs in their propensity to prescribe these drugs, thereby leading to ‘postcode prescribing’. 

Thirdly, it also raises legal issues in that if there is a complaint about the failure to issue a prescription for a drug the CCG does not want GPs to prescribe, it will be the GP and not the CCG who will be at risk and who will have to defend any complaint made by the patient or their representative (many GPs seem unaware of this and seem to think – mistakenly – that if they are following a CCG policy they will somehow be protected against complaints).

Each CCG carrying its own evidence review, public and professional consultation, and developing its implementation policy also results in considerable duplication of effort. At a time when the NHS has been asked to make considerable efficiency savings, we can't afford to waste financial, managerial and clinical resources on this scale.

Finally, such restrictions may disproportionately affect poorer patients who will be less able to pay for OTC drugs. 

If CCGs think the NHS can no longer afford to prescribe certain drugs, then they should group together and raise this issue with the Department of Health and NHS England; and ask them to add these drugs to the list of drugs that cannot be prescribed on the NHS.


Popular posts from this blog

What will Brexit mean for the NHS?

On the 29 March 2017, the Prime Minister of the UK Theresa May, formally notified the European Union (EU) Council President, Donald Tusk, of the UK’s intention to leave the EU. Theresa May’s letter to Donald Tusk triggers a two-year process during which the UK will have to negotiate both the terms of its exit from EU and the arrangements that will replace those we have had for over 40 years with the other member states of the EU. The consequences of the United Kingdom’s departure from the EU (commonly referred to as ‘Brexit’) will be wide-ranging and will affect all areas of UK’s society, including the National Health Service (NHS).

For the NHS, Brexit comes at a time when it faces many other major challenges. These include severe financial pressures, rising workload, increased waiting times for both primary care and specialist services, and shortages of health professionals in many key areas (such as in general practice and in emergency departments). The NHS also faces challenges fr…

Improving how secondary care and general practice in England work together: the NHS Standard Contract

Due to the increasing pressures on general practices within the National Health Service in England, the interface between primary and secondary care, and the division of labour between these, has become an important issue. This has long been an area prone to difficulties and conflict, the consequences of which can directly impact the quality and safety of patient care, particularly for patients with chronic conditions who regularly transition between these two sectors. In an article published in the Journal of the Royal Society of Medicine, Amy Price and I explore the measures recently implemented in the NHS Standard Contract which aim to target common issues at the primary–secondary care interface, with an aim to reducing inappropriate general practitioner workload in England. We discuss the context behind the implementation of the NHS Standard Contract as well as current concerns and areas for further consideration.

The current crisis in primary care means the NHS Standard Contract…

Dr Demis Hassabis, Co-Founder and CEO of DeepMind, Speaks about AI in Healthcare

On 28 September 2017, I attended the Annual Institute of Global Health Innovation Lecture: Artificial General Intelligence and Healthcare, delivered by Dr Demis Hassabis, co-founder and CEO of Google DeepMind. Artificial intelligence is the science of making machines smart argued Dr Hassabis, so how can we make it improve the healthcare sector? Dr Hassabis then went on to describe the work that DeepMind was carrying out in healthcare in areas such as organising information, deep learning to support the reporting of medical images (such as scans and pathology slides), and biomedical science. Dr Hassabis also discussed the challenges of applying techniques such as reinforcement learning in healthcare. He concluded that artificial intelligence has great scope for improving healthcare; for example, by prioritising the tasks that clinicians had to carry out and by providing decision support aids for both patients and doctors. Dr Hassabis also discussed some of the ethical issues in using …